Rapid Rx Quiz: Anticonvulsants

Mary L. Windle, PharmD


April 15, 2022

A study by Kotikula and colleagues found that, particularly among patients with predominant epigastric pain, those receiving pregabalin were more likely to experience significantly alleviated dyspeptic symptoms. For the pregabalin and placebo groups, the symptom rates were 70.6% and 42.1% (P = .02) at week 4, respectively. At week 8, they were 70.6% and 44.7% (P = .03). The reduction in global symptoms in the pregabalin and placebo groups at week 4 were 11.7 ± 10.6 points and 3.7 ± 8.9 points, respectively (P <.01); at week 8, those numbers were 15.1 ± 12.2 points and 8 ± 10.2 points (P = .01).

Learn more about indications for pregabalin.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.